AlphAIAlphAI — Financial news for AI agents
medicaldevice-network.comNOV 42 min read$ZBH

Zimmer Biomet stock rises 9% after reporting positive Q3

Zimmer Biomet reported Q3 revenue of $2bn, up 3.1% YoY, and raised its 2026 outlook. Earnings per share are now expected to be $8.50-$8.60, with revenue growth forecasted at 4.4%-4.9%. Shares rose 9.1% to $105.90 at market open. The company's CEO attributed the growth to its diversification strategy and innovation.

Original reporting
medicaldevice-network.com
Published Nov 4, 2026, 4:22 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 4, 2026, 4:24 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$ZBH
Bullish
high confidence
Mentioned
$ZBH
Relevance
9/10
AlphAI data visualization · based on medicaldevice-network.com
Decision brief

The 30-second read

$ZBHBullishHigh
01

Why it matters

The earnings beat and guidance lift are likely to drive short‑term buying pressure, with the stock already up over 9% at open.

02

Market read

The strong earnings and guidance raise make Zimmer Biomet a near‑term rally candidate, influencing medtech sector sentiment.

03

What to watch

Potential supply‑chain constraints or slower adoption of new technology & data segment could temper growth.

Relevance 9/10Novelty 9/10Timing: pre‑market today

Background

Zimmer Biomet, a leading orthopaedics device maker listed on the NYSE, released its Q3 earnings ahead of market open, highlighting revenue growth and an upgraded 2026 outlook.

Company-level read

Ticker impact

$ZBHBullishHigh confidence
Context

Zimmer Biomet reported Q3 results with revenue above $2bn and raised its 2026 earnings guidance, causing a 9.1% pre‑market price jump.

Expected impact

likely upward pressure as the market prices in higher earnings guidance and revenue growth.

Evidence & confidence

The company lifted its EPS outlook to $8.50‑$8.60 and revenue growth to 4.4‑4.9%, both above prior expectations, and the stock already rallied 9% on the news.

Market effects

Sector

Orthopaedics and medtech peers may see renewed investor interest as Zimmer Biomet's guidance raise signals sector strength.

Regional

U.S. healthcare stocks could benefit from the positive earnings surprise.

Global

Limited to U.S. and global medtech investors tracking growth trends.

Counterpoint

What could challenge this read

The guidance raise may already be priced in; a pullback could occur if execution falls short of expectations.

Key entities

  • Executive
    Ivan Tornos

    CEO of Zimmer Biomet who commented on the results.

Read at source← All news

StoryZimmer Biomet posts Q3 2026 results and lifts full‑year outlook

Also covered by

5 outlets

Related articles

NOV 4
$ZBHHighAI 8/10

Zimmer Biomet Q3 Profit Falls, Lifts FY26 Outlook

Zimmer Biomet (ZBH) reported Q3 net earnings of $191.6M ($1.0 per share), down from $230.9M ($1.16 per share) a year earlier. Adjusted earnings were $362.8M ($1.90 per share), with net sales rising 3.1% to $2.06B. The company raised its FY26 adjusted EPS outlook to $8.50-$8.60 and revenue growth forecast to 4.4%-4.9%.

rttnews.com2 min
NOV 4
$ZBHHighAI 8/10

Zimmer Biomet beats Q3 estimates, raises guidance

Zimmer Biomet (ZBH) reported Q3 adjusted EPS of $1.90, beating estimates by $0.02, with revenue of $2.06B, up 3.1% YoY. The company raised its 2026 adjusted EPS guidance to $8.50-$8.60. Shares rose 1.5% post-results. Key segments like Hips and Technology & Data showed strong growth, while Knees declined.

investing.com2 min
NOV 4
$ZBHHighAI 8/10

Zimmer Biomet (NYSE:ZBH) exceeds Q3 2026 expectations

Zimmer Biomet reported Q3 2026 revenue of $2.06B, beating estimates by 1.1% and growing 3.1% YoY. Adjusted EPS was $1.90, a 1% beat. Management raised full-year adjusted EPS guidance to $8.55. Operating margin declined to 14.9%, while free cash flow margin increased to 18.1%. Constant currency revenue grew 3.7% YoY, down from 8.6% last quarter.

finance.yahoo.com1 min
NOV 4
$ZBHHighAI 8/10

Zimmer: Q3 Earnings Snapshot

Zimmer Biomet Holdings Inc. (ZBH) reported Q3 profit of $191.6M, or $1 per share, beating estimates. Adjusted EPS was $1.90, and revenue was $2.06B, also exceeding forecasts. The company expects full-year EPS of $8.50-$8.60. (Zacks)

finance.yahoo.com2 min
NOV 4
$ZBHHighAI 8/10

Zimmer Biomet Q3 Sales Rise 3.1%; Raises 2026 Growth Guidance

Zimmer Biomet reported Q3 2026 net sales of $2.063 billion, up 3.1% YoY. EPS was $1.00, adjusted EPS was $1.90. The company raised its 2026 guidance, expecting 3.0%–3.5% revenue growth and adjusted EPS of $8.50–$8.60. Strong performance in Hips, S.E.T., and Technology & Data, Bone Cement and Surgical franchises. Extended agreement with THINK Surgical and opened a new training facility.

tradingview.com1 min